Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (477)	12/26/2000 5:12:36 PM
From: Vector1	Read Replies (1) \| Respond to of 804

Miljenko, It concerns me when we disagree on a stock. I think CELG is cheap at $31 per share. The company has about $300m in cash and will be cash positive for the year. Furthermore I do not see Thalomid sales slowing. Scrip growth has not been a good incicator for Thalomid because most cases currently are precribed in hospital settings.The following positive events should drive the stock going forward. * Data from the Phase II trial of the first SelCID for the treatment of Crohn s disease (1Q:01). * Initiation of Phase III trial with Thalomid in MDS (1Q:01). * Initiate Phase II/III trial of Thalomid for the treatment of colorectal cancer (1Q:01). * Announcement of Phase I/II data for IMiDs in the treatment of multiple myeloma (2Q:01). * Announcement of Thalomid Total Therapy data for the treatment of early multiple myeloma (2Q:01). * IND for a SERM for the treatment of cancer (2Q:01). * FDA approval of Attenade (late 2Q:01 or early 3Q:01). * Launch of Attenade (3Q:01). * Announcement of a drug development partnership coming out of the Signal pipeline (1H:01).